

# Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea

**Marta Marin-Oto**

Aragón Health Research Institute

**David Sanz-Rubio**

Aragón Health Research Institute

**Fernando Santamaría-Martos**

Hospital Arnau de Vilanova, IRB-Lleida

**Ivan Benitez**

Hospital Arnau de Vilanova, IRB-Lleida

**Ana L. Simon**

Aragón Health Research Institute

**Marta Forner**

Aragón Health Research Institute

**Pablo Cubero**

Aragón Health Research Institute

**Ana Gil**

Aragón Health Research Institute

**Manuel Sanchez-de-laTorre**

Hospital Arnau de Vilanova, IRB-Lleida

**Ferran Barbe**

Hospital Arnau de Vilanova, IRB-Lleida

**José M. Marin** (✉ [jmmarint@unizar.es](mailto:jmmarint@unizar.es))

Aragón Health Research Institute

---

## Research Article

**Keywords:** sRAGE, smokers, chronic obstructive pulmonary disease, obstructive sleep apnoea

**Posted Date:** April 14th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1534378/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

# Abstract

**Background.** Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-inflammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap.

**Methods.** Plasma levels of sRAGE were measured in 317 subjects at baseline (57 healthy nonsmokers [HNS], 84 healthy smokers [HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap).

**Results.** After adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (-12.5%,  $p = 0.005$ ), COPD (-14.8%,  $p < 0.001$ ) and OSA-COPD overlap (-12.3%,  $p = 0.02$ ) compared with HNS. There were no differences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change significantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased significantly.

**Conclusions.** The levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP significantly ameliorated sRAGE levels in patients with OSA who also had COPD.

## Background

Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction and persistent airway inflammation due to the inhalation of noxious gases such as cigarette smoke [1], whereas obstructive sleep apnoea (OSA) is characterized by periodic collapse of the upper airway during sleep [2]. COPD and OSA are frequent diseases affecting more than 10% of the adult population each [1, 3]. The term “overlap syndrome” was introduced to describe the association of both conditions in a single patient. Patients with “overlap syndrome” showed an increased risk of death and hospitalization [4, 5].

One of the main common consequences of these diseases is local and systemic hypoxia [5–7]. Systemic inflammation and oxidative stress develop because of chronic hypoxia [6] and in response to repetitive intermittent hypoxia during sleep in OSA [7]. Both COPD and OSA have been associated with an increased risk for cardiovascular morbidity and mortality, and it is possible that elevated systemic inflammation and oxidative stress could play an important role as intermediary mechanisms. sRAGE, the soluble isoform of the receptor for advanced glycation end products (RAGE), prevents AGE-enhanced MAP kinase activity, generates oxidative stress and inhibits the activation of proinflammatory signalling cascades [8]. Some studies suggest that sRAGE is protective against proinflammatory conditions and that RAGE could be a potential therapeutic target in chronic inflammatory diseases [9]. Reduced levels of sRAGE are related to both an increased risk of cardiovascular events [10] and progression of emphysema [11]. The mechanisms that justify this effect have not been elucidated. The role of sRAGE in OSA has not yet been studied.

Both COPD and OSA are two diseases where hypoxia plays a crucial pathogenic role, contributing to inflammation and oxidative stress; therefore, these conditions may be associated with a lower level of sRAGE. We hypothesized that there is a reduction in plasma levels of sRAGE in OSA and COPD, with an additive decreasing effect in those patients with both conditions (overlap syndrome). The aim of the present study was to assess the plasma levels of sRAGE in OSA, COPD and OSA-COPD overlap patients and its relationship with disease severity variables such as lung function and hypoxemia. Afterwards, we assessed the effect of treatment with continuous positive airway pressure (CPAP) in patients with OSA on sRAGE levels.

## Methods

### Design and setting of the study

The present study is an ancillary study of the Epigenetics Modification in Obstructive Sleep Apnoea (EPIOSA) study (ClinicalTrials.gov identifier: NCT02131610). The EPIOSA Study is a longitudinal cohort of consecutive subjects referred to the Sleep Clinic at the Hospital Universitario Miguel Servet due to suspected OSA between March 2013 and March 2016 [12]. The methods used are provided in more detail [see Additional file 1]. Full inclusion and exclusion criteria are shown in Additional file 1: Table S1. In brief, subjects aged 18 to 70 years and free of any additional chronic comorbid condition other than OSA or COPD were included in the cohort and visited every year at the clinic. Study procedures were carried out in accordance with the World Medical Association Declaration of Helsinki. The research protocol was approved by the Ethics and Clinical Research Committee of the Aragon Institute of Health Sciences (IRB03/2013), and informed consent was obtained from each subject.

### Clinical Data, Measurements, And Follow-up

Demographic, anthropometric, and clinical data were obtained during recruitment and at the annual visit. Daytime somnolence was assessed using the Epworth Sleepiness Scale (ESS) [13]. Home-unattended sleep studies were performed at baseline and after one-year follow-up. Recordings were manually scored following national guidelines [14] (Additional file 1: Methods). At baseline, spirometry was performed on all participants according to American Thoracic Society (ATS)/European Respiratory Society (ERS) recommendations [15].

Subjects were categorized into five groups: a) healthy nonsmokers (HNS); b) asymptomatic healthy smokers with normal spirometry and no OSA (HS); c) OSA if apnoea–hypopnoea index (AHI) was > 5 events per hour of sleep recording; d) COPD as defined by a smoking history  $\geq 10$  pack-years and a postbronchodilator forced expiratory volume at first second -FEV<sub>1</sub>-/forced vital capacity < 0.7 after 400  $\mu$ g of albuterol; and e) OSA-COPD overlap when OSA and COPD coexist in the same patient. From fasting blood samples, plasma was stored at -80°C for later batch analyses of sRAGE following a standard procedure (Additional file 1: Methods).

The Spanish Respiratory Society Guidelines for the management of OSA were applied [14]. Specifically, CPAP therapy was recommended if AHI  $\geq$  30 events/hour or AHI 5.0–30 and excessive daytime sleepiness (ESS  $\geq$  10) interfered with daily activities. All participants were followed at the Sleep Clinic at 3 and 12 months after the initial visit.

## Statistical Analysis

Mean (and standard deviation) if normally distributed or median (and interquartile range) if not normally distributed and absolute frequency (and percentage) were computed, respectively for quantitative and qualitative data to report differences between the studied groups. The Mann–Whitney test or Fisher’s test was conveniently performed to statistically assess differences between groups. Different linear models considering the main effects of OSA, COPD and overlap on sRAGE levels but also models considering only OSA, COPD and their interaction were fitted. Different covariates were considered for the adjusted analyses, and R squared was used to measure the performance of the models in terms of explained variability. Compared to HNS, the reduction (in percentage) in the sRAGE levels was computed for each group and combination. For the cohort, as a whole and within each group studied, we used linear regression analysis to evaluate the association of COPD-related severity variables (FEV<sub>1%</sub> pred) and OSA-related severity variables (AHI or men SpO<sub>2</sub>) with sRAGE circulating levels after natural log-transformation (age, sex, BMI and smoking status included as covariates). Differences between baseline and one-year follow-up sRAGE levels were studied using the Wilcoxon signed-rank test. The threshold for significance was set at 5% (alpha = 0.05), and all analyses were performed using STATA v.12.1 software (College Station, Tx, USA).

## Results

### Population

A total of 317 subjects were included in the study, and 294 had also been evaluated at the one-year follow-up (Figure 1). The demographics and clinical characteristics of the subjects at baseline are shown in Table 1. As groups, COPD and overlap patients were older and more likely to be male than healthy subjects. OSA and overlap had a higher BMI than healthy subjects or COPD patients. Patients with COPD and overlap had more pack-years than OSA and healthy smokers.

### Plasma levels of sRAGE

At baseline, plasma levels of sRAGE were similar between HNS and HS. Nevertheless, median plasma sRAGE was significantly lower in OSA (1148 pg.mL<sup>-1</sup>), COPD (1066 pg.mL<sup>-1</sup>) and overlap groups (1047 pg.mL<sup>-1</sup>) than in healthy nonsmoker subjects (1421 pg.mL<sup>-1</sup>; all  $p < 0.01$ ) (Table 1).

<b>Table 1.</b> Baseline clinical characteristics of participants.					
	<b>Healthy nonsmokers</b>	<b>Smoker</b>	<b>OSA</b>	<b>COPD</b>	<b>Overlap</b>
Number	57	84	79	62	35
Age, yrs	43.8 ± 12.0	51.8 ± 10.2	47.3 ± 9.6	60.6 ± 5.7	61.7 ± 4.7
Male, no. (%)	30 (53)	44 (52)	64 (81)	47 (68)	29 (83)
BMI, kg/m <sup>2</sup>	27.1 ± 4.3	26.1 ± 3.8	29.5 ± 3.5	26.3 ± 4.4	31.7 ± 5.1
Active smokers,%	0	34	18	31	27
Smoking, pack-yrs	0	21.3 ± 15.6	14.1 ± 17.4	41.2 ± 28.3	43.2 ± 24.7
FEV <sub>1</sub> , % pred	98.2 ± 11.8	91.4 ± 14.5	96.1 ± 13.6	63.5 ± 20.1	60.2 ± 19.8
AHI, events/h	2.4 ± 1.5	2.9 ± 1.4	43.7 ± 22.4	1.9 ± 2.1	29.6 ± 9.3
T90, %	1.7 ± 4.9	2.7 ± 6.6	19.1 ± 19.9	11.4 ± 17.6	29.8 ± 23.6
sRAGE, pg/mL	1421 (1019-1740)	1401 (1136-1731)	1148 (773-1394)	1066 (537-1281)	1047 (757-1191)
Data are presented as the mean ± sd, except for sRAGE which are presented as median (interquartile range). <i>HNS</i> healthy nonsmokers, <i>HS</i> healthy smokers, <i>BMI</i> body mass index, <i>FEV1</i> forced expiratory volume in 1 second, <i>AHI</i> apnoea–hypopnea index, <i>T90</i> % of time with arterial oxygen saturation <90%, <i>sRAGE</i> soluble receptor for advanced glycation end-products.					

Adjusted regression models showed that sRAGE levels were significantly lower in OSA patients (reduction of 12.5%,  $p = 0.005$ ), COPD patients (reduction 14.8%,  $p < 0.001$ ) and patients with overlap (reduction 10.4%,  $p = 0.034$ ) than in healthy nonsmokers (Table 2). There were no differences in the levels of sRAGE when comparing OSA with COPD or overlap patients. Overall, these results support the individual effect of OSA and COPD on sRAGE levels but not an additive effect (Figure 2). In a secondary analysis, when subjects were separated based on smoking status (active versus nonactive smokers), plasma sRAGE remained significantly lower in the OSA, COPD and overlap patients compared to healthy smokers (Additional file 1: Figure S1).

<b>Table 2.</b> Association of diagnostic groups with circulating levels of sRAGE.			
	<b>Beta (SE)</b>	<b>Adjusted p values</b>	<b>Reduction of sRAGE</b>
Intercept	2417.279 (240.523)		
SA	-231.915 (81.951)	0.005	-9.6%
COPD	-357.286 (89.676)	< 0.001	-14.8%
Overlap syndrome	-240.357 (82.341)	0.034	-10.4%

### Association of sRAGE with clinical characteristics

In the cohort as a whole (Table 3), simple univariate linear regression analysis showed that plasma sRAGE was inversely related to age, male sex, BMI, pack-years of cigarette exposure, AHI and percentage of nighttime with SpO<sub>2</sub> < 90% -T90- (all p values < 0.001) and directly related to FEV<sub>1</sub>% predicted (p < 0.001). However, in multivariate analysis and after removing BMI and pack-years of smoke exposure that showed a high grade of collinearity with OSA and COPD, respectively, and sex that showed collinearity with both disorders, sRAGE remained directly related to the level of FEV<sub>1</sub>% predicted and inversely related to AHI and T90. When the analysis was restricted to subjects without COPD or OSA (n = 141), the sRAGE levels only correlated with BMI (p = 0.008) (Additional file 1: Table S2). In patients with OSA only (n = 79), there was an inverse relationship between sRAGE plasma levels and AHI (p = 0.013) (Additional file 1: Table S3), whereas in patients with COPD only (n = 62), circulating levels were independently related to FEV<sub>1</sub>% predicted (p = 0.001) (Additional file 1: Table S4). In patients with both diseases (n = 35), there was an independent relationship between the sRAGE levels and FEV<sub>1</sub>% (p = 0.013) and T90 (p = 0.037) as a surrogate of the degree of nocturnal hypoxemia (Additional file 1: Table S5).

<b>Table 3.</b> Univariate and multivariate association of sRAGE ( $\log_{10}$ ) with clinical characteristics in the whole cohort.				
<b><i>Univariate</i></b>	<b>Beta</b>	<b>SE</b>	<b>t test</b>	<b><i>p</i> Value</b>
Age, yrs	-0.0077	0.0182	2.91	< 0.001
BMI, kg/m <sup>2</sup>	-0.0206	0.0045	4.55	< 0.001
Smoking, pack-yrs	-0.0032	0.0007	4.15	< 0.001
FEV <sub>1</sub> , % pred	0.0052	0.0009	6.01	< 0.001
AHI, events/h	-0.0032	0.0008	4.06	< 0.001
T90, %	-0.0078	0.0012	6.15	< 0.001
<b><i>Multivariate</i></b>				
FEV <sub>1</sub> , % pred	0.0022	0.0005	3.16	0.002
AHI, events/h	-0.0015	0.0005	2.63	0.012
T90, %	-0.0039	0.0015	2.61	0.010
<i>BMI</i> body mass index, <i>FEV1</i> forced expiratory volume in 1 second, <i>AHI</i> apnoea–hypopnoea index, <i>T90%</i> of time with arterial oxygen saturation <90%, <i>sRAGE</i> soluble receptor for advanced glycation end-products				

## Follow-up

One-year follow-up was completed by 294 participants (92.7%). Before the scheduled visit to one year, five patients died (1 HS, 1 OSA, 2 COPD and 1 with overlap), 16 subjects declined a re-examination (7 HNS, 8 HS, 1 OSA and 1 with overlap), and two could not be reached (1 HNS and 1 HS). The mean time of CPAP use among patients with OSA or with overlap syndrome was 5.8 hours per night (range 3.1–9.4) and 4.8 (range 2.6–7.7), respectively. In healthy nonsmokers, healthy smokers, and COPD patients, there were no changes in sRAGE levels (Additional file 1: Table S6 and Additional file 1: Figure S2). There were also no changes in patients with OSA or overlap syndrome not treated with CPAP. However, in patients receiving CPAP, sRAGE levels increased significantly both in patients with OSA and in patients with overlap syndrome ( $p = 0.009$  and  $p = 0.019$ , respectively) (Table S6 and Figure 3). The percentage change in sRAGE was not related to the baseline severity of COPD or OSA assessed by % predicted of FEV<sub>1</sub> and AHI, respectively, or to the hours of CPAP use (data not shown).

## Discussion

The present study shows that plasma concentrations of the anti-inflammatory molecule sRAGE are reduced in patients with COPD and in patients with OSA. Furthermore, plasma sRAGE levels are not significantly reduced in overlap syndrome with respect to COPD or OSA. Moreover, to the best of our knowledge, this is the first study that has investigated the effect of CPAP on plasma levels of sRAGE.

The receptor for advanced glycation end products is found on endothelial and inflammatory cell surfaces and binds to circulating advanced glycation end products, activating a proinflammatory protein cascade that contributes to systemic oxidative stress and inflammation. sRAGE is the soluble isoform of RAGE and acts as a protective decoy by buffering inflammatory ligands, thus decreasing inflammatory injury. Therefore, low levels of sRAGE are a biomarker of deficient inflammatory control. In addition, activation of nuclear factor- $\kappa$ B is an absolute requirement for both IL-6 and IL-8 via RAGE [16]. sRAGE concentrations remain relatively stable over time in community studies [17]. In both OSA and COPD, NF- $\kappa$ B is activated, and consequently, sRAGE may be related to the activation and maintenance of this factor and for extension in the maintenance of inflammation in COPD and OSA [18, 19]. We did not find an overlap effect on sRAGE levels. This finding could suggest that the pathways involved in the decrease in plasma sRAGE are the same for both diseases, producing a ceiling effect. The associations described in the present study are in agreement with previous reports that indicate reduced plasma sRAGE levels related to COPD and OSA [20, 21]. The decrease in COPD is related to disease severity in concordance with the ECLIPSE cohort, where levels of circulatory sRAGE were significantly reduced in accordance with advanced GOLD stage [22]. We also found an independent relationship between AHI and sRAGE in OSA, in agreement with another study [21]. In patients with only OSA or only COPD, robust signals of tissue hypoxia, such as T90 or mean nocturnal SaO<sub>2</sub>, showed no relationship with plasma levels of sRAGE. This suggests an independent role of the obstructive events “per se” and flow limitation, respectively, with the role of nocturnal hypoxemia as a secondary intermediate factor to explain the low levels of sRAGE in these diseases.

The results of this study indicate that both COPD and OSA hypoxia-related diseases promote a decline in anti-inflammatory patient conditions. Moreover, the presence of these two diseases manifesting together does not have an additive effect, so the increased cardiovascular morbidity in overlap syndrome would not be explained for an increased anti-inflammatory decline for the combination of these two hypoxia-related diseases. A similar ceiling effect has been previously postulated for the influence of OSA and obesity on metabolic hormones [23]. In our study, other proinflammatory biomarkers were not evaluated; therefore, we could not establish their relationship with sRAGE levels at baseline or over time. In COPD, there is consensus in considering this disease to be associated with systemic inflammation [1]. However, in OSA, our data and those of other researchers indicate that circulating inflammatory biomarkers are not elevated and do not change with CPAP treatment [24–26]. Of interest in this study has been to find a clear reduction of a circulating anti-inflammatory marker such as sRAGE in patients with OSA, with or without associated COPD and to verify how it increased after one year of treatment with CPAP. This finding should be checked with further studies, but it raises the hypothesis of a new intermediate mechanism to explain the relationship between OSA and cardiovascular diseases and the benefit of CPAP to reduce the risk of morbidity and mortality in these patients. Interestingly, in patients with subclinical atherosclerosis,

low levels of sRAGE were associated with a high intima-media thickness and carotid atheroma plaques [27]. We have previously demonstrated that in OSA patients (with or without coexisting COPD), subclinical atherosclerosis is highly prevalent and that there is an accelerating ageing process [28]. We also have reported that CPAP slows this phenomenon [29], so the long-term benefit of CPAP therapy in patients with OSA could in part be explained by increasing sRAGE with CPAP therapy.

Our study has limitations. First, this study is not a randomized trial; therefore, a cause-effect relationship of the modification of sRAGE levels in relation to CPAP treatment cannot be established. Nevertheless, we studied relatively well-matched subject groups and provided one-year follow-up data on OSA treatment effects. Second, we used home-based respiratory devices rather than the gold standard inpatient overnight polysomnography. However, this approach is well established in clinical care [30–32]. Finally, our sample population was drawn from hospital-based respiratory clinics; hence, we cannot extend our results to the general patient population.

## Conclusions

The present study identifies that plasma sRAGE is reduced in patients with COPD and in patients with OSA in a dose-effect relationship according to the severity of both entities. Moreover, overlap of COPD and OSA does not lead to an additive effect. Nocturnal hypoxemia does not explain these changes in either of the two entities. Effective treatment by CPAP of subjects with obstructive apnoeas (with or without associated COPD) increases the level of sRAGE, while in healthy subjects and COPD without OSA, these levels do not change over time. Future longitudinal studies are needed to ascertain whether sRAGE has utility in predicting comorbidities and mortality in OSA, COPD and OSA/COPD overlap syndrome.

## Abbreviations

AGE

advanced glycation end products

AHI

apnoea–hypopnoea index

ATS

American Thoracic Society

BMI

Body mass index

COPD

Chronic obstructive pulmonary disease

CPAP

Continuous positive airway pressure

EPIOSA

Epigenetic Modification in Obstructive Sleep Apnoea

ERS

European Respiratory Society  
ESS  
Epworth Sleepiness Scale  
FEV1  
Forced expiratory volume in the first second  
HNS  
Heathy nonsmokers  
NS  
Nonsmokers  
OSA  
Obstructive sleep apnoea  
SpO2  
Pulse oxygen saturation  
sRAGE  
soluble receptor for advanced glycation end-products  
T90  
Percentage of nighttime with SpO2 < 90%

## **Declarations**

### **Acknowledgements**

We thank all staff at the Sleep Unit and Pulmonary Department of the Hospital Universitario Miguel Servet and all the patients who participated in the study.

### **Authors' Contributions**

Study conception and design: MM-O, DS-R, ALS, FS-M, FB, JMM. The acquisition of the data: MM-O, DS-R, ALS, MF, PC, AVG, IB, MST, FB, FS-M, MST, F.B. Analysis or interpretation of the data: MM-O, DS-R, MF, PC, AVG, FS-M, IB, JMM. Writing original draft preparation: MM-O, FB, JMM. Funding acquisition, MST, FB, JMM. All authors read and approved the final version of the manuscript.

### **Funding**

The EPIOSA study (NCT02131610) was supported by Grants Number PI12/02175, PI15/01940 and PI18/01524 from the Instituto Salud Carlos III, Spanish Ministry of Health, Madrid, Spain and the European Regional Development Fund (FEDER) and by a Grant Number 01/2010 from the SADAR-PneumoAragón, Zaragoza, Spain.

### **Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

## Ethics approval and consent to participate

The study EPIOSA Study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics and Clinical Research Committee of the Aragon Institute of Health Sciences (IRB03/2013). Informed consent was obtained from each subject before study entry.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup>Translational Research Unit, Aragón Health Research Institute, Zaragoza, Spain. <sup>2</sup>Respiratory Department, Hospital Arnau de Vilanova, IRB-Lleida, Lleida, Spain. <sup>3</sup>CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. <sup>4</sup>Respiratory Service, Hospital Universitario Miguel Servet & Department of Medicine, University of Zaragoza, both at Zaragoza, Spain.

## References

1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med.* 2017; 195: 557–82. <https://doi.org/10.1164/rccm.201701-0218PP>
2. Veasey, S.C.; Rosen, I.M. Obstructive Sleep Apnea in Adults. *N Engl J Med.* 2019; 380: 1442–49. <https://doi.org/10.1056/NEJMc1906527>.
3. Durán J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 year. *Am J Respir Crit Care Med.* 2001; 163:685–89. <https://doi.org/10.1164/ajrccm.163.3.2005065>.
4. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. *Am J Respir Crit Care Med.* 2010; 182:325–31. <https://doi.org/10.1164/rccm.200912-1869OC>.
5. McNicholas WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. *Eur Respir Rev.* 2013; 1; 22:365–75. <https://doi.org/10.1183/09059180.00003213>.
6. Eltzhig HK, Carmeliet P. Hypoxia and Inflammation. *N Engl J Med.* 2011; 364: 656–65. <https://www.nejm.org/doi/full/10.1056/NEJMc1103019>
7. Sánchez-de-la-Torre M, Campos-Rodriguez F, Barbé F. Obstructive sleep apnoea and cardiovascular disease. *Lancet Respir Med.* 2013; 1:61–72. [https://doi.org/10.1016/S2213-2600\(12\)70051-6](https://doi.org/10.1016/S2213-2600(12)70051-6).

8. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. *J Biol Chem*. 1997; 272:17810–4. <https://doi.org/10.1074/jbc.272.28.17810>.
9. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. *Curr Med Chem*. 2006; 13:1971–98. <https://doi.org/10.2174/092986706777585013>.
10. Raposeiras-Roubín S, Rodiño-Janeiro BK, Paradela-Dobarro B, Grigorian-Shamagian L, García-Acuña JM, Aguiar-Souto P, Jacquet-Hervet M, Reino-Maceiras MV, González-Juanatey JR, Álvarez E. Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. *PLoS One*. 2013; 13:8(9):e74302. <https://doi.org/10.1371/journal.pone.0074302>
11. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agustí A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, T al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. *Lancet Respir Med*. 2013; 1:129–36. [https://doi.org/10.1016/S2213-2600\(13\)70006-7](https://doi.org/10.1016/S2213-2600(13)70006-7)
12. Marin JM, Artal J, Martin T, Carrizo SJ, Andres M, Martin-Burriel I, Bolea R, Sanz A, Varona L, Godino J, et al. Epigenetics modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA study. *BMC Pulm Med*. 2014; 12;14:114. <https://doi.org/10.1186/1471-2466-14-114>
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991; 14:540–545. <https://doi.org/10.1093/sleep/14.6.540>
14. Lloberes P, Durán-Cantolla J, Martínez-García MÁ, Marín JM, Ferrer A, Corral J, Masa JF, Parra O, Alonso-Álvarez ML, Terán-Santos J. Diagnosis, and treatment of sleep apnea-hypopnea syndrome. Spanish Society of Pulmonology and Thoracic Surgery. *Arch Bronconeumol*. 2011; 47:143–156. <https://doi.org/10.1016/j.arbres.2011.01.001>
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al; ATS/ERS Task Force. Standardization of spirometry. *Eur Respir J*. 2005; 26:319–38. <https://doi.org/10.1183/09031936.05.00034805>
16. Rasheed Z, Akhtar N, Haqqi TM. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear fac-tor- $\kappa$ B in human osteoarthritis chondrocytes. *Rheumatology* 2011; 50:838–51. <https://doi.org/10.1093/rheumatology/keq380>
17. Bower JK, Pankow JS, Lazo M, Christenson E, Hoogeveen RC, Ballantyne CM, Halushka MK, Astor BC, Selvin E. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). *Clin Biochem*. 2014; 47:132–134. <https://doi.org/10.1016/j.clinbiochem.2013.11.005>

18. Schuliga M. NF-kappaB Signaling in Chronic Inflammatory Airway Disease. *Biomolecules*. 2015; 5:1266–83. <https://doi.org/10.3390/biom5031266>
19. Williams A, Scharf SM. Obstructive sleep apnea, cardiovascular disease, and inflammation—is NF-kappaB the key?. *Sleep Breath*. 2007; 11:69–76. <https://doi.org/10.1007/s11325-007-0106-1>
20. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. *Eur Respir J*. 2011;37:516–22. <https://doi.org/10.1183/09031936.00029310>
21. Volna J, Kemlink D, Kalousova M, Vávrová J, Majerová V, Mestek O, Svarcová J, Sonka K, Zima T. Biochemical oxidative stress-related markers in patients with obstructive sleep apnea. *Med Sci Monit*. 2011; 17:CR491-R497. <https://doi.org/10.12659/msm.881935>
22. Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciruba FC, Zhang Y, Ortega VE, et al. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD. *Respir Res*. 2021; 22:127. <https://doi.org/10.1186/s12931-021-01686-z>
23. Sánchez-de-la-Torre M, Mediano O, Barceló A, Piérola J, de la Peña M, Esquinas C, Miro A, Durán-Cantolla J, Agustí AG, Capote F, et al. The influence of obesity and obstructive sleep apnea on metabolic hormones. *Sleep Breath*. 2012; 16:649–56. <https://doi.org/10.1007/s11325-011-0552-7>
24. Vicente E, Marin JM, Carrizo SJ, Osuna CS, González R, Marin-Oto M, Forner M, Vicente P, Cubero P, Gil AV, et al. Upper airway and systemic inflammation in obstructive sleep apnea. *Eur. Respir. J*. 2016; 48:1108–17. <https://doi.org/10.1183/13993003.00234-2016>
25. Kohler M, Ayers L, Pepperell JC, Packwood KL, Ferry B, Crosthwaite N, Craig S, Siccoli MM, Davies RJ, Stradling JR. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnea: a randomised controlled trial. *Thorax*. 2009; 64:67–73. <https://doi.org/10.1136/thx.2008.097931>
26. Stradling JR, Craig SE, Kohler M, Nicoll D, Ayers L, Nunn AJ, Bratton DJ. Markers of inflammation: data from the MOSAIC randomized trial of CPAP for minimally symptomatic OSA. *Thorax*. 2015; 70:181–82. <https://doi.org/10.1136/thoraxjnl-2014-205958>
27. Moriya S, Yamazaki M, Murakami H, Maruyama K, Uchiyama S. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE. *J Stroke Cerebrovasc Dis*. 2014; 23:2540–46. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.05.037>
28. Khalyfa A, Marin JM, Qiao Z, Rubio DS, Kheirandish-Gozal L, Gozal D. Plasma exosomes in OSA patients promote endothelial senescence: effect of long-term adherent continuous positive airway pressure. *Sleep*. 2020, 3;43(2):zsz217. <https://doi.org/10.1093/sleep/zsz217>
29. Cortese R, Sanz-Rubio D, Kheirandish-Gozal L, Marin JM, Gozal D. Epigenetic age acceleration in obstructive sleep apnea is reversible with adherent treatment. *Eur Respir J*. 2022 Jan 27:2103042. Epub ahead of print. <https://doi.org/10.1183/13993003.03042-2021>
30. Rosen CL, Auckley D, Benca R, Foldvary-Schaefer N, Iber C, Kapur V, Rueschman M, Zee P, Redline S. A multisite randomized trial of portable sleep studies and positive airway pressure autotitration versus

laboratory-based polysomnography for the diagnosis and treatment of obstructive sleep apnea: the HomePAP study. *Sleep*. 2012; 35:757–67. <https://doi.org/10.5665/sleep.1870>

31. Andreu AL, Chiner E, Sancho-Chust JN, Pastor E, Llombart M, Gomez-Merino E, Senent C, Barbé F. Effect of an ambulatory diagnostic and treatment programmed in patients with sleep apnea. *Eur Respir J*. 2012; 39:305–12. <https://doi.org/10.1183/09031936.00013311>
32. Corral J, Sánchez-Quiroga MÁ, Carmona-Bernal C, Sánchez-Armengol Á, de la Torre AS, Durán-Cantolla J, Egea CJ, Salord N, Monasterio C, Terán J, et al.; Spanish Sleep Network. Conventional polysomnography is not necessary for the management of most patients with suspected obstructive sleep apnea. Noninferiority, randomized controlled trial. *Am J Respir Crit Care Med*. 2017; 196:1181–90. <https://doi.org/10.1164/rccm.201612-24970C>

## Figures





Figure 1

Study flowchart. Numbers of participants who were screened, assigned to a study group, and included in the analyses after 1-year follow-up according to treatment. OSA: obstructive sleep apnoea; COPD: chronic obstructive pulmonary disease; CPAP continuous positive airway pressure.



**Figure 2**

Soluble receptor for advanced glycation end-products (sRAGE) values. Median and corresponding interquartile range for each group. Reduction (in percentage) in the sRAGE levels versus the healthy nonsmoker group with the corresponding adjusted p values. HNS: healthy nonsmokers; HS: healthy smokers; OSA: obstructive sleep apnoea; COPD: chronic obstructive pulmonary disease




Figure 3

Individual values of sRAGE at baseline and at the end of the first year of follow-up. OSA: obstructive sleep apnoea; CPAP continuous positive airway pressure.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalmaterialSolubleRAGEinCOPD.docx](#)